fluvastatin / Generic mfg. - LARVOL DELTA

Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma (ASH 2025) - "The most studied of these, PIK001, showed robust single agent anti-MM activity invitro, synergized with established anti-MM agents (including immunomodulatory drugs, proteasomeinhibitors, venetoclax, and selinexor), and retained efficacy in lenalidomide-resistant models. Notably, PIK001 combined with the HMG-CoA reductase inhibitor fluvastatinresulted in antagonistic effects, highlighting the functional relevance of cholesterol metabolism in PIKfyveinhibitor-induced cytotoxicity. Upregulation of cholesterol biosynthesis genes following PIK001 exposurewas also demonstrated ex vivo.Our findings establish PIKfyve inhibition as a compelling target in MM, elucidates distinct mechanisms ofresistance, and reveal unexpected links to cholesterol metabolism and tumor immunity as aconsequence of autophagy disruption in MM—laying a strong preclinical foundation for furthermechanistic studies and therapeutic development."

Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • SQSTM1

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Gross tumor assessment is not a reliable measure of the efficacy of chemo-preventive agents for breast cancer in preclinical mouse models. (PubMed, Sci Rep) - "Animals were treated with fluvastatin and/or aspirin for 16 weeks and the experiment was concluded at 22 weeks, and all the mammary glands removed for histologic assessment...These analyses suggest that there is poor concordance between the gross tumor measurements and histological tumor assessment in a mouse model of breast cancer. Thus, gross tumor measurement alone is insufficient for determining chemopreventive efficacy in preclinical animal models."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Statins Kill Acute Myeloid Leukemia Cells through Low-Density Lipoprotein Receptor-Mediated Unfolded Protein Response Activation (ASH 2024) - "However, the SWOG S0919 trial, which evaluated a combination of idarubicin, cytarabine, and pravastatin in relapsed/refractory AML cases, reported a high complete response (CR/CRi) rate of 75%...The cells were cultured in the presence of either 2µM atorvastatin, 2µM fluvastatin, or dimethyl sulfoxide (DMSO) as a control for 20 days...Furthermore, the identification of UPR stress as a major cause of AML cell death opens possibilities for developing novel molecular targeted therapies. In conclusion, our study revealed that statin-induced AML cell death is mediated by LDLR-induced UPR activation, providing new insights into potential therapeutic strategies for AML treatment."

Acute Myelogenous Leukemia • Dyslipidemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Targeted Protein Degradation • ANXA5 • ATF4 • CASP3 • LDLR

Identification of basement membrane-based prognostic signature and potential therapeutic drugs in hepatocellular carcinoma. (PubMed, Transl Cancer Res) - "Lastly, we conducted a search for potential therapeutic drugs such as fluvastatin and navitoclax tailored to the high-risk subgroup identified by BMS, aiming to enhance personalized treatment strategies for HCC in the future. Our findings highlight the potential of BM-associated molecular classifiers like BMS in improving the diagnosis, prognosis, and treatment of HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

The effects and potential mechanisms of statins on growth, development and pathogenicity in Botrytis cinerea. (PubMed, World J Microbiol Biotechnol) - "Fluvastatin, atorvastatin, simvastatin and lovastatin strongly suppressed hyphal growth of B. cinerea, with EC50 values of 0.66, 3.0, 10.0 and 22.21 µg/mL respectively...We demonstrated that statins exert inhibitory effects on mycelial growth, development and pathogenicity of B. cinerea, with HMGR predicted as the molecular target. These findings collectively indicated that HMGR was a potential novel control target and statins could be used as lead compounds for developing novel agents."

Journal • Infectious Disease

Computational structural studies of SGLT2-related polypharmacy. (PubMed, PLoS One) - "The indication of interactions with several compounds likely to be prescribed alongside SGLT2 inhibitors, such as antibiotics, statins, and antiplatelet agents, warrants further investigation of the potential for polypharmacological complications."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • PDZK1IP1

Elucidating the Inhibitory Potential of Statins Against Oncogenic c-Met Tyrosine Kinase Through Computational and Cell-based Studies. (PubMed, Iran J Pharm Res) - "Machine learning led the experiment to find fluvastatin and pitavastatin as the two compounds with the highest inhibitory effects. However, no significant reduction in c-Met phosphorylation was observed by western blot. No relation between the statins' inhibitory effect and the c-Met pathway on cancerous cells could be reported."

Journal • Gastric Cancer • Oncology • Solid Tumor • HGF • MET

Nanospiky Copper Peroxide as Lactate-Modulating Nanoadjuvant To Induce Cuproptosis and Pyroptosis for Enhanced Tumor Immunotherapy. (PubMed, Nano Lett) - "Herein, nanospiky copper peroxide nanoadjuvant has been produced via a straightforward ion substitution process between Cu2+ and calcium carbonate nanoparticles in water followed by reaction with hydrogen peroxide, then loaded with the lactate metabolism regulator fluvastatin sodium and modified with the tumor-targeting molecule hyaluronic acid (defined as NSCuO2@F@HA). The obtained NSCuO2@F@HA nanoparticles not only regulate lactate metabolism by suppressing the extracellular efflux of lactic acid to reverse the immunosuppressive TME but also increase the content of Cu2+ and reactive oxygen species within tumor cells to effectively induce cuproptosis and pyroptosis of tumor cells, further enhancing the presentation of tumor-associated antigens. In consequence, NSCuO2 nanoparticles will offer a powerful reference for nanomaterials serving as therapeutic nanoadjuvants to enhance the efficacy of antitumor immunotherapy."

Journal • Oncology

Safety and Efficacy of Moderate vs High Intensity Statin Therapy After Nontraumatic Intracerebral Hemorrhage: A Real-World Evidence Analysis. (PubMed, Cerebrovasc Dis) - "In this large, real-world analysis, moderate-intensity statins demonstrated statistically significant but modest reductions in recurrent ICH, ischemic stroke, composite vascular events, and all-cause mortality compared with high-intensity statins, without increased adverse events. These findings may support preferential use of moderate-intensity statin therapy in selected post-ICH patients pending confirmation from randomized trials. While these observational findings suggest potential benefits of moderate-intensity statin therapy in selected post-ICH patients, confirmation from randomized controlled trials is needed before definitive clinical recommendations can be made."

HEOR • Journal • Real-world evidence • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Hepatology • Ischemic stroke • Liver Failure

Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma. (PubMed, Cancer Res) - "Importantly, both compounds displayed the same efficacy in 2D and 3D culture models, and a single treatment with entinostat improved survival in an immunocompetent mouse model compared with fluvastatin and standard cisplatin-pemetrexed chemotherapy, which showed similar anti-tumor effects. Combination of entinostat with anti-PD1 even eradicated tumors in several mice and immunized them against re-transplantation of tumor cells. Overall, the drug sensitivity data provided by this study represents a resource to facilitate future clinical investigations to improve treatment of PM."

IO biomarker • Journal • Preclinical • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Sarcoma • Solid Tumor • Transplantation • BAP1 • TAFAZZIN

Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma. (PubMed, Neuro Oncol) - "Targeting the SE complex enhances TMZ chemosensitivity in GBM, providing a promising therapeutic avenue to overcome drug resistance and improve clinical outcomes."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • HDAC1 • PDGFB • SOX2

Autophagy Disruption via PIKfyve Inhibition Strikingly Upregulates Cholesterol Metabolism in Multiple Myeloma (IMS 2025) - "Synergy studies between PIK001 and cholesterol pathway inhibitors, such as fluvastatin, lycorine, and U18666A, showed strong antagonism, highlighting the importance of cholesterol in mediating the effects of PIK001... Taken together, PIKfyve inhibition induces an increase in cholesterol biosynthesis and its combination with cholesterol pathway inhibitors antagonizes the cytotoxic effects of PIK001. These findings may inform the design of more effective combinations when targeting PIKfyve in MM."

Hematological Malignancies • Multiple Myeloma • FDFT1 • HMGCS1 • LAMP1

Physico-chemical characterization of fucoidans from three Sargassums species with assessment of antiviral, antioxidant, cytotoxicity and hypocholesterolemic actions: In vitro. (PubMed, Int J Biol Macromol) - "Furthermore, the examined cold Sargassum species extracts displayed cytotoxic potential against hepatocellular carcinoma (HepG2), with an LD50 of 48.3 μg/mL for S. dentifolium cold polysaccharide, compared with doxorubicin (29.58 μg/mL). asperifolium cold and hot fucoidans exhibited hypocholesterolemic effects of 89 % and 70 %, respectively, compared to fluvastatin. In conclusion, fucoidan has a promising role for hepatic ailments."

Journal • Preclinical • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Integrating single-cell RNA sequencing and artificial intelligence for multitargeted drug design for combating resistance in liver cancer. (PubMed, NPJ Precis Oncol) - "The model shows robust predictive performance (R²: 0.9867, MSE: 0.0581) and identifies important drug candidates, such as Gadobenate Dimeglumine and Fluvastatin, and describes repurposing opportunities in network analysis, enhancing computational drug discovery for novel treatments. This research sheds new light on HCC tumor evolution, immune suppression, and the potential drug target based on the viewpoint of the importance of single-cell approaches in liver cancer research."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • APOA2 • APOE • SERPINA1 • XIST

Fluvastatin mitigates the testicular toxicity of Azathioprine via regulating mTOR pathway and restoring autophagy/apoptosis balance. (PubMed, Reprod Toxicol) - "Gene transcription indicated that AZA disrupts the mammalian target of the rapamycin (mTOR) cascade and the autophagic and apoptotic-related genes in testes, thus impairing the blood-testis barrier (BTB) and spermatogenesis. Fluvastatin exhibited antioxidant and anti-inflammatory defense, regulated the mTOR pathway, restored the lost autophagy/apoptosis balance, and improved the architectural and immunohistochemical alterations. Therefore, fluvastatin can be considered a candidate for future usage to combat AZA-induced testicular toxicity."

Journal • Inflammation • CAT • IL10 • IL1B • IL6 • NLRP3 • VIM

Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration. (PubMed, Am J Ophthalmol) - "In this study of patients with type 2 diabetes and dyslipidemia, medium- and high-intensity, but not low-intensity, statin therapies were associated with a reduced risk of AMD. Further research is needed to confirm these findings and elucidate the underlying mechanisms."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Macular Degeneration • Metabolic Disorders • Ophthalmology • Retinal Disorders • Type 2 Diabetes Mellitus

Targeting Cholesterol-Dependent Piezo1 Activation Impairs Amoeboid Migration in Melanoma Cells. (PubMed, bioRxiv) - "Statins, including Fluvastatin and Pitavastatin, suppress amoeboid migration of melanoma cells in confined environments by reducing intracellular cholesterol. Our findings highlight cholesterol biosynthesis as essential for invasive cell behavior and identify it as a therapeutic vulnerability. Importantly, elevated cholesterol pathway activity correlates with reduced survival in melanoma patients, underscoring the clinical relevance of targeting this pathway to limit metastasis."

Journal • Melanoma • Oncology • Solid Tumor

Investigation of simvastatin and fluvastatin permeation across cell membrane models using molecular dynamics simulations. (PubMed, J Chem Phys) - "These findings highlight how membrane composition and asymmetry govern passive drug diffusion and suggest that selective membrane interactions may reflect the differential anticancer potential of statins. The results provide mechanistic insights into structure-permeability relationships and support the strategic use of realistic membrane models in drug discovery and repurposing efforts."

Journal • Oncology

Osteogenic Potential of Simvastatin and Fluvastatin in an Organotypic Bone Model. (PubMed, Pharmaceuticals (Basel)) - "In contrast, higher-dose treatment (10 µM) attenuated these effects. These findings underscore the dose-dependent osteoinductive potential of statins and support their application in bone repair strategies within carefully defined therapeutic windows."

Journal • ACAN • COL1A2 • RUNX2 • SOX9 • SPP1

Statins and Their Effect on Hearing: An All of Us Database Study. (PubMed, Ann Otol Rhinol Laryngol) - "In this study, the All of Us database was used to investigate the relationship between statins and hearing loss/tinnitus. Results indicate a potential ototoxic association of statins on hearing and tinnitus."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Otorhinolaryngology

HBV-miR-3 induces hepatic cholesterol accumulation by targeting ABCA1: evidence for potential benefits of statin usage. (PubMed, J Lipid Res) - "Interestingly, widely prescribed cholesterol-lowering drugs (simvastatin, atorvastatin and fluvastatin) could inhibit pro-oncogenic effects of HBV-miR-3. In sum, HBV-miR-3 may represent the 'missing link' between CHBV and altered lipid metabolism in hepatocytes. Statin-mediated inhibition of HBV-miR-3-induced intrahepatic lipid accumulation and cell proliferation has potential clinical utility and merits further investigation."

Journal • Hepatitis B • Infectious Disease • Inflammation • Metabolic Disorders • Oncology • ABCA1

Bidirectional relationship between statins and the gut microbiota: Implications for Cardiovascular Health, Diabetes, and Cancer. (PubMed, Xenobiotica) - "This manuscript explores the complex interplay between statins and the gut microbiota, highlighting implications for cardiovascular health, metabolic disorders, and cancer. In contrast to previous studies, this work investigates both the shared and distinct effects of commonly prescribed statins, including atorvastatin, simvastatin, fluvastatin, and rosuvastatin, underscoring the relevance of microbiome-informed and personalized approaches to therapy."

Journal • Review • Cardiovascular • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database. (PubMed, PLoS One) - "Based on FAERS database, six statins are significantly associated with liver injury, and fluvastatin, atorvastatin, and simvastatin had the greatest risk of DILI."

Adverse events • Journal • Retrospective data • Hepatology • Liver Failure

Integrative transcriptome-based drug repurposing in tuberculosis. (PubMed, bioRxiv) - "Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways...This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis."

Journal • Immune Modulation • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CXCR2 • MYD88 • RELA